Chemomab Therapeutics Ltd. Sponsored ADR CMMB 深 沪
已收盘 04-02 16:00:00 美东时间
1.56
-0.030
-1.89%
华盛通- 最 高1.60
- 今 开1.56
- 成交量 4.79万股
- 最 低 1.5419
- 昨 收 1.59
- 总市值 1123.26万
- 52周最高 5.88
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 1.35
- 委 比 -13.64%
- 总股本 720.04万
- 历史最高 736.00
- 量 比 1.64
- 振 幅 3.65%
- 历史最低 1.35
- 每 手 1
- 风险率 1.30%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Chemomab Therapeutics Q4 EPS $(0.24) Beats $(0.40) Estimate
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.24) per share which beat the analyst consensus estimate of $(0.40) by 40 percent. This is a 62.5 percent increase over losses of $(0.64) per share from
03-19 20:27
Chemomab Therapeutics Announces Year End and Fourth Quarter 2025 Financial Results and Provides a Corporate Update
<b> Chemomab Therapeutics 在2025年取得重要进展 </b> 公司完成二期临床试验并获得FDA批准开展三期试验，展示了其药物nebokitug在治疗原发性硬化性胆管炎（PSC）中的潜力。此外，已在多个科学会议发表数据，进一步确认其疾病修饰能力及其在其他纤维炎症性疾病中的潜在应用。公司正与战略伙伴合作推动三期临床试验的开展，并继续探索nebokitug在其他适应症中的应用。
03-19 12:00
Chemomab Therapeutics to Participate in Oppenheimer 36th Annual Healthcare Life Sciences Conference
Chemomab Therapeutics Ltd., a biotech company developing therapeutics for fibro-inflammatory diseases, announced that its CEO and senior management will present at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on February 26, 2026. The presentation, available on Chemomab's investor relations website for 90 days, will cover the company's innovative treatments, including nebokitug, a first-in-class monoclonal antibody targ...
02-17 13:00
Chemomab Therapeutics Data From Phase 2 SPRING Study Shows Nebokitug Was Safe, Well Tolerated In Participants With Primary Sclerosing Cholangitis At Up To 48 Weeks Of Treatment
Chemomab Therapeutics Ltd. (Nasdaq: CMMB), (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that the results of
2025-12-02 21:16
Chemomab to Participate in Oppenheimer’s Movers in Rare Disease Summit
Chemomab Therapeutics Ltd. announced that its co-founder and CEO, Dr. Adi Mor, will present at Oppenheimer's Movers in Rare Disease Summit on December 11, 2025, in New York City. Dr. Mor will provide a corporate overview and hold one-on-one meetings with attendees. Chemomab is a biotech company developing innovative therapeutics for fibro-inflammatory diseases, particularly focusing on nebokitug, a first-in-class monoclonal antibody targeting CCL...
2025-11-24 13:00
Chemomab Therapeutics Advances PSC Treatment with Phase 3 Trial
Chemomab Therapeutics Ltd. ( ($CMMB) ) has released its Q3 earnings. Here is a ...
2025-11-22 11:53
Chemomab Therapeutics GAAP EPS of $0.00
Chemomab Therapeutics press release (CMMB): Q3 GAAP EPS of $0.00. Net loss was $1.7 million, or a net loss of less than one-half of one cent per basic and diluted ordinary share for the third quarter ...
2025-11-20 21:33
Chemomab Therapeutics Q3 EPS $(0.28) Beats $(0.40) Estimate
Chemomab Therapeutics (NASDAQ:CMMB) reported quarterly losses of $(0.28) per share which beat the analyst consensus estimate of $(0.40) by 30 percent. This is a 65 percent increase over losses of $(0.80) per share from
2025-11-20 21:30
Chemomab Therapeutics Announces Third Quarter 2025 Financial Results and Provides Corporate Update
Chemomab Therapeutics Ltd announced positive updates on its nebokitug Phase 3 trial design for primary sclerosing cholangitis (PSC), receiving support from both the FDA and EMA for a single registration trial using a clinical event composite endpoint. Data from the Phase 2 SPRING trial's open-label extension (OLE) showed favorable safety and consistent improvements in key biomarkers, further reinforcing nebokitug's disease-modifying potential. Th...
2025-11-20 13:00
Chemomab To Present Abstracts Highlighting New Clinical Data From Nebokitug Phase 2 SPRING Trial In Primary Sclerosing Cholangitis, At AASLD 2025
— Phase 2 SPRING Trial Open Label Extension Showed Favorable Safety and Consistent Improvements in Key Biomarkers in PSC Patients Treated with Nebokitug for Up to 48 Weeks——New Clinical Data Provides Insights on
2025-11-06 21:09
